Samatasvir
- Generic Name
- Samatasvir
- Drug Type
- Small Molecule
- Chemical Formula
- C47H48N8O6S2
- CAS Number
- 1312547-19-5
- Unique Ingredient Identifier
- 21P699C5FC
- Background
Samatasvir has been used in trials studying the treatment of Hepatitis C, Chronic, Chronic Hepatitis C Virus, and Chronic Hepatitis C Infection.
Pharmacokinetics of IDX719 in Participants With Normal and Impaired Hepatic Function (MK-1894-008)
- First Posted Date
- 2013-08-08
- Last Posted Date
- 2016-01-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 36
- Registration Number
- NCT01919125
Drug-Drug Interaction Between IDX719, Simeprevir, TMC647055 and Ritonavir When Administered in Combination in Healthy Participants (MK-1894-007)
Phase 1
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2013-07-25
- Last Posted Date
- 2016-01-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 34
- Registration Number
- NCT01907724
Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005)
Phase 2
Completed
- Conditions
- Chronic Hepatitis C Virus
- Interventions
- Biological: Pegylated interferon (Peg-IFN)Other: Samatasvir matching placebo
- First Posted Date
- 2013-05-14
- Last Posted Date
- 2015-04-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 143
- Registration Number
- NCT01852604
Study to Evaluate Drug-Drug Interaction Between IDX719 and Simeprevir in Healthy Participants (MK-1894-004)
- First Posted Date
- 2013-03-19
- Last Posted Date
- 2016-01-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 42
- Registration Number
- NCT01813513
To Evaluate the Effect of Ritonavir or Omeprazole on the Pharmacokinetics of Samatasvir (IDX719) in Healthy Participants (MK-1894-006)
Phase 1
Completed
- Conditions
- Chronic Hepatitis C Infection
- Interventions
- First Posted Date
- 2013-03-19
- Last Posted Date
- 2016-01-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 24
- Registration Number
- NCT01813552
Study of Hepatitis C Virus (HCV) Nonstructural Protein 5a (NS5A) Inhibitor IDX719 in Healthy and HCV-Infected Participants (MK-1894-001)
- First Posted Date
- 2012-01-11
- Last Posted Date
- 2015-04-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 130
- Registration Number
- NCT01508156
A Open-label Study to Evaluate the Relative Bioavailability of Samatasvir (IDX184) and Food Effect in Healthy Male Participants (MK-2355-006)
- First Posted Date
- 2011-04-14
- Last Posted Date
- 2016-01-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 12
- Registration Number
- NCT01335607
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath